Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults

Abstract

Trusted evidence. Informed decisions. Better health.Cochrane Database of Systematic Reviews Analysis 2.5. Comparison 2 Sensitivity analysis (fixed e ect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 5 Erythrocyte sedimentation rate

The Likelihood of Preventing Respiratory Exacerbations in Children and Adolescents with either Chronic Suppurative Lung Disease or Bronchiectasis

“…A dose–response relationship between azithromycin use and an increase in macrolide-resistant strains of S. pneumoniae and S. aureus in the nasopharynx was also observed in a prospective study of 79 remote Australian children with CSLD or bronchiectasis conducted between 2004 and 2008 (56). These findings are consistent with those of the 2015 Cochrane review (57), which reported a threefold increase in antibiotic-resistant bacteria.…”

The Likelihood of Preventing Respiratory Exacerbations in Children and Adolescents with either Chronic Suppurative Lung Disease or Bronchiectasis

“…A dose–response relationship between azithromycin use and an increase in macrolide-resistant strains of S. pneumoniae and S. aureus in the nasopharynx was also observed in a prospective study of 79 remote Australian children with CSLD or bronchiectasis conducted between 2004 and 2008 (56). These findings are consistent with those of the 2015 Cochrane review (57), which reported a threefold increase in antibiotic-resistant bacteria.…”

Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention

“…Antibiotics administered for 4-83 weeks (inhaled or oral) against 'short term as needed' or placebo showed a significant reduction in pulmonary exacerbations (271 per 1000 in intervention compared with 546 per 1000 in controls). 93 There was also a reduction in hospitalizations (37 per 1000 in intervention compared with 87 per 1000 in controls). No significant changes in FEV 1 (reported in 88% of studies) were shown but reductions in sputum purulence and volume, systemic inflammatory markers and SGRQ were described in the studies when these were measured.…”

Assessing 5-year follow-up of core outcome set uptake for Bronchiectasis and Hidradenitis Suppurativa: a review of trial registry entries

“…Lack of uptake relating to specific outcomes may not result from lack of relevance to the disease but instead as a result of other barriers such as confusion regarding how to measure each outcome, caused by limited standardisation of measurement tools for both diseases 14–16…”

The Likelihood of Preventing Respiratory Exacerbations in Children and Adolescents with either Chronic Suppurative Lung Disease or Bronchiectasis

“…A dose–response relationship between azithromycin use and an increase in macrolide-resistant strains of S. pneumoniae and S. aureus in the nasopharynx was also observed in a prospective study of 79 remote Australian children with CSLD or bronchiectasis conducted between 2004 and 2008 (56). These findings are consistent with those of the 2015 Cochrane review (57), which reported a threefold increase in antibiotic-resistant bacteria.…”

Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention

“…Antibiotics administered for 4-83 weeks (inhaled or oral) against 'short term as needed' or placebo showed a significant reduction in pulmonary exacerbations (271 per 1000 in intervention compared with 546 per 1000 in controls). 93 There was also a reduction in hospitalizations (37 per 1000 in intervention compared with 87 per 1000 in controls). No significant changes in FEV 1 (reported in 88% of studies) were shown but reductions in sputum purulence and volume, systemic inflammatory markers and SGRQ were described in the studies when these were measured.…”

Assessing 5-year follow-up of core outcome set uptake for Bronchiectasis and Hidradenitis Suppurativa: a review of trial registry entries

“…Lack of uptake relating to specific outcomes may not result from lack of relevance to the disease but instead as a result of other barriers such as confusion regarding how to measure each outcome, caused by limited standardisation of measurement tools for both diseases 14–16…”

The Likelihood of Preventing Respiratory Exacerbations in Children and Adolescents with either Chronic Suppurative Lung Disease or Bronchiectasis

“…A dose–response relationship between azithromycin use and an increase in macrolide-resistant strains of S. pneumoniae and S. aureus in the nasopharynx was also observed in a prospective study of 79 remote Australian children with CSLD or bronchiectasis conducted between 2004 and 2008 (56). These findings are consistent with those of the 2015 Cochrane review (57), which reported a threefold increase in antibiotic-resistant bacteria.…”

Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention

“…Antibiotics administered for 4-83 weeks (inhaled or oral) against 'short term as needed' or placebo showed a significant reduction in pulmonary exacerbations (271 per 1000 in intervention compared with 546 per 1000 in controls). 93 There was also a reduction in hospitalizations (37 per 1000 in intervention compared with 87 per 1000 in controls). No significant changes in FEV 1 (reported in 88% of studies) were shown but reductions in sputum purulence and volume, systemic inflammatory markers and SGRQ were described in the studies when these were measured.…”

Assessing 5-year follow-up of core outcome set uptake for Bronchiectasis and Hidradenitis Suppurativa: a review of trial registry entries

“…Lack of uptake relating to specific outcomes may not result from lack of relevance to the disease but instead as a result of other barriers such as confusion regarding how to measure each outcome, caused by limited standardisation of measurement tools for both diseases 14–16…”